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Article
Evaluation of polycaprolactone matrices
for the intravaginal delivery
of metronidazole in the treatment
of bacterial vaginosis
Meenakshi Pathak1, Mark Turner2, Cheryn Palmer3 and Allan GA Coombes1,4
Abstract
Microporous, poly (e-caprolactone) (PCL) matrices loaded with the antibacterial, metronidazole were produced by
rapidly cooling suspensions of drug powder in PCL solutions in acetone. Drug incorporation in the matrices increased
from 2.0% to 10.6% w/w on raising the drug loading of the PCL solution from 5% to 20% w/w measured with respect to
the PCL content. Drug loading efficiencies of 40–53% were obtained. Rapid ‘burst release’ of 35–55% of the metro-
nidazole content was recorded over 24 h when matrices were immersed in simulated vaginal fluid (SVF), due to the
presence of large amounts of drug on matrix surface as revealed by Raman microscopy. Gradual release of around 80% of
the drug content occurred over the following 12 days. Metronidazole released from PCL matrices in SVF retained
antimicrobial activity against Gardnerella vaginalis in vitro at levels up to 97% compared to the free drug. Basic modelling
predicted that the concentrations of metronidazole released into vaginal fluid in vivo from a PCL matrix in the form of an
intravaginal ring would exceed the minimum inhibitory concentration of metronidazole against G. vaginalis. These findings
recommend further investigation of PCL matrices as intravaginal devices for controlled delivery of metronidazole in the
treatment and prevention of bacterial vaginosis.
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Introduction
Bacterial vaginosis (BV) is one of the most common
genital conditions occurring in women of child bearing
age1 and is caused by the displacement of normal vagi-
nal lactobacilli by other species notably Gardnerella
vaginalis, Mycoplasma homonis and anaerobic bac-
teria such as peptostretococci, Prevotella spp. and
Mobiluncus spp.2 BV is associated with adverse preg-
nancy outcomes including post-partum, post-abortion
and post-hysterectomy infections. BV increases
women’s risk of acquiring pelvic inflammatory disease
and potentially some sexually transmitted infections
(STIs) such as chlamydia, gonorrheae and HIV/AIDS
by inducing changes in the mucosal immune environ-
ment of the vagina.2–4 BV is estimated to have a mean
prevalence of 14% when considering both developed
and developing countries, but as the microflora of the
vaginal ecosystem changes throughout the menstrual
cycle, under the influence of exogenous hormones and
during reproductive life in most women it is difficult to
estimate the true prevalence or impact of BV.5 In the
United States, BV affects approximately 80,000 preg-
nant women per year, resulting in an increased
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incidence of preterm delivery or low-birth weight.
Treatment can reduce these risks and may in turn
reduce the number of associated perinatal deaths and
neurologic abnormalities in infants.6
BV, when treated, is generally managed by using
metronidazole (MTZ), which belongs to the nitro-imi-
dazole class of antibiotics and exhibits broad spectrum
activity against most Gram-negative and Gram-positive
anaerobic bacteria.7 MTZ is particularly attractive for
the treatment of BV because it also eradicates any coex-
isting trichomoniasis, an STI caused by the protozoa,
Trichomonas vaginalis.3 MTZ is generally administered
orally in tablet form (2 g single dose or 400mg,
12-hourly for 7 days) but this route is often associated
with adverse gastrointestinal side effects, nausea, head-
ache, anorexia and occasionally vomiting. The bitter or
metallic taste of oral dosage forms presents a further
disadvantage. The side effects have been avoided by
administration of MTZ as solid vaginal formulations
such as pessaries and tablets but the residence time is
short, necessitating frequent administration.8 Semi-
solid intravaginal gels incorporating MTZ (0.75%)
require daily administration of approximately 5 g gel
for 5 days but semi-solid preparations are messy to
apply, prone to leakage and concerns exist over effect-
ive coverage of the vaginal epithelium. These factors
have contributed to the recent upsurge of interest in
intravaginal ring (IVR) devices for sustained delivery
of antiviral8,9 and antibacterial microbicides.10
Recently, polyanionic dendrimers constructed from L-
lysine with precise configurations of oligomeric moi-
eties (e.g. naphthalene disulfonate) have attracted
attention as microbicides.11 Dendrimer SPL-7013 in
particular has been reported to display selective anti-
bacterial activity against G. vaginalis at a concentration
of 5mg/mL using the agar dilution method and low
activity against normal vaginal Lactobacillus flora
thus holding out promise as a future therapy or
prophylaxis for BV. However, vaginal formulations of
dendrimer in Carbopol gel may need to contain 40–
100mg dendrimer in 4–5 g of gel for effective daily
dosing and application may be required for 3–4 days
per week which renders the approach inconvenient for
the user.12,13
IVRs offer advantages of low and continuous dosing
over extended time periods, reduced side effects, self-
administration and improved patient compliance.
Conventional IVRs produced from silicone elastomer
or poly (ethylene vinyl acetate) (pEVA) have been used
clinically for many years for delivery of oestrogen (hor-
mone replacement therapy) and etonogestrel and ethi-
nyl oestradiol (contraceptive purposes).14 IVRs are
being evaluated for sustained release of the non-nucleo-
side reverse transcriptase inhibitor, Dapivirine as
an anti-HIV microbicide and acyclovir for herpes
prophylaxis.15,16 Conventional IVRs do however dis-
play a number of disadvantages for microbicide deliv-
ery; they are generally restricted to delivery of low
molecular weight, hydrophobic drugs such as
Dapivirine. In addition, manufacture involves heating
at 80C for silicone elastomer or 140C for pEVA
which could degrade thermally-sensitive compounds.
These problems have been circumvented by introducing
more complex IVR designs and manufacturing tech-
niques, whereby drug-containing pods are inserted
into preformed rings.17 The synthetic polyester, poly
(e-caprolactone) (PCL) has been investigated exten-
sively for many years for production of a range of
drug delivery systems including, microparticles, nano-
particles, films and fibres.18 PCL nanoparticles loaded
with the immunosuppressant cyclosporine, for exam-
ple, have been reported to decrease the nephrotoxicity
of the drug and efficiently target lymphocytes.19 We
have previously shown that microporous PCL matrices
prepared by precipitation casting20 or rapid cooling
techniques13 are effective for sustained delivery of
small hydrophobic drug molecules (progesterone),21
hydrophilic entities (gentamicin sulphate)20 and macro-
molecules such as enzymes with retained activity.22
More recently, the potential utility of these materials
was demonstrated for vaginal delivery of the antibac-
terial, ciprofloxacin, in the treatment of gonorrhoea.
Drug loadings of 7.3–15% were obtained and drug
released into SVF retained high antibacterial activity
against N. gonorrhoeae.10 Here we describe sustained
delivery of MTZ from PCL matrices intended for pro-
duction of IVRs in the treatment of BV.
Materials and methods
Materials
PCL (Mw 115,000 Da, CAPA 6500) was obtained from
Solvay Interox, Warrington, UK. MTZ, glucose, urea,
bovine serum albumin, potassium hydroxide, calcium
chloride, glycerol, lactic acid and acetic acid were pur-
chased from Sigma-Aldrich, Australia. G. vaginalis
stock culture in glycerol broth was supplied by
Micromon, Monash University, Clayton, Victoria,
Australia. Horse blood agar, heart infusion broth
(HIB), CO2 generation kit and antimicrobial suscepti-
bility blank discs were obtained from Oxoid,
Basingstoke, UK.
Production of MTZ-loaded PCL matrices
PCL solutions of concentration 15% w/v were prepared
by dissolving the polymer in acetone at 50C. MTZ was
ground to a fine powder and added to the PCL solution
to produce suspensions of concentrations 5%, 10%,
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15% and 20% w/w of the PCL content. The resulting
suspension was homogenized for 30 s at 5000 rpm
using a Silverson SL27 homogenizer (Silverson
Machines, Chesham, Bucks, UK). The suspension
was poured into a polypropylene syringe body (3mL)
which was used as a mould and cooled in ethanol at
80C for 2 h to allow crystallisation of PCL. The har-
dened matrices were removed from the moulds and
immersed in 10mL ethanol for 24 h to extract acetone
by solvent exchange. Samples were removed from etha-
nol and left to dry under ambient conditions to evap-
orate residual solvents. The final matrices were in the
form of cylinders of diameter 6.5 0.5mm and length
45.0 5mm.
Determination of MTZ content of PCL matrices
Four sections were cut from the top, upper-middle,
lower-middle and base of cylindrical PCL matrices to
determine the uniformity of drug distribution with in
the matrices. Samples were weighed and dissolved in
2mL of dichloromethane (DCM). Precipitation of
PCL was induced by adding 5mL of 30% methanol
followed by shaking overnight (Vibrax VXR, IKA,
Werke Staufen, Germany) to evaporate DCM and
obtain partitioning of the drug into the methanol
phase. The MTZ content of the methanol phase was
determined by using UV spectrophotometry (Varian,
Cary 50 Bio, Agilent Technology, USA) at an absorb-
ance wavelength of 319 nm by comparison with a cali-
bration curve constructed using a series dilution of
MTZ in 30% methanol (4–20 mg/mL). Experiments
were performed in triplicate to obtain values of actual
drug loading and loading efficiencies of PCL matrices.
Morphology of MTZ-loaded PCL matrices
The morphology of the surface and interior of drug-free
and drug-loaded PCL matrices was examined using a
JSM 6460LA scanning electron microscope (SEM,
JEOL, Japan). Specimens were mounted on aluminium
SEM stubs using carbon tabs and sputter coated with
platinum using an Eiko-Sputter coater automatic
mounting press, prior to examination at a voltage
of 5 kV.
Differential scanning calorimetry
The thermal characteristics of PCL matrices were inves-
tigated using differential scanning calorimetry (DSC)
(DSC 1 STARe System, Mettler Toledo, Switzerland)
under a nitrogen atmosphere. Samples of drug-free and
MTZ-loaded PCL matrices were weighed, placed in
sealed aluminium pans and heated over the temperature
range 100C to 150C at a rate of 10C/min. The peak
melting point, glass transition temperature (Tg) and
heat of fusion data were obtained using the DSC soft-
ware facility. The crystallinity of PCL matrices loaded
with different amounts of MTZ was examined to iden-
tify any changes with drug loading. Crystallinity (%)
was estimated using a value of 139.5 J/g for the heat of
fusion of fully crystalline PCL.20
Hardness testing of PCL matrices
Hardness testing of drug-free and MTZ-loaded matri-
ces was carried out using a CT3 Texture
Analyzer (Brookfield Engineering Laboratories Inc.,
Middleboro, MA). As-moulded cylinders were
mounted horizontally and compressed locally at a
speed of 0.1mm/min to a depth of 2.0mm using a
2mm diameter, flat-ended, cylindrical probe (TA39).
The hardness (or indentation resistance) of each
sample was calculated from the applied force measured
at a depth of 2mm. A pEVA IVR (Nuvaring,
Schering-Plough Pty limited, New South Wales,
Australia) was subjected to the same test procedure
for comparison.
In vitro release of MTZ from PCL matrices
Cylindrical sections of MTZ-loaded PCL matrices
(length 45mm) were subjected to a release study in
SVF. Prior to testing both ends of each sample were
sealed by dipping in 5% w/v solution of PCL in acetone
followed by drying in air. Experiments were performed
in triplicate. Each sample was placed separately in
10mL of SVF and retained at 37C in an incubator.
SVF was prepared according to the method of Owen
and Katz23 and contained 3.51 g NaCl, 1.40 g KOH,
0.222 g Ca(OH)2, 0.018 g bovine serum albumin,
2.00 g lactic acid, 1.00 g acetic acid, 0.16 g glycerol,
0.4 g urea and 5.0 g glucose up to 2L of distilled
water. The pH was adjusted to 4.2 using 10% HCl.
The release media were collected and replaced with
fresh media daily for 12 days. The concentration of
drug in the release medium was analysed by UV spec-
trophotometry (Varian, Cary 50 Bio, Agilent technol-
ogy, USA) at 319 nm by comparison with a standard
curve produced using a series dilution of MTZ in SVF.
Separate release samples were stored at 4C for anti-
microbial testing.
Raman spectroscopy
Raman mapping of 10% MTZ-loaded PCL matrices
was performed to characterise the drug distribution
for correlation with drug release behaviour. A 1mm
thick disk was taken from the middle of drug-loaded
PCL matrices, placed on a glass slide and scanned using
356 Journal of Biomaterials Applications 29(3)
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a Raman microscope (Nicolet Almega XR Dispersive
Raman, Thermoscientific, USA) at spatial intervals
of 100 mm.
In vitro assay of antimicrobial activity
The antimicrobial activity of MTZ released from the
PCL matrices was assayed with G. vaginalis using the
disc diffusion method. G. vaginalis was stored as stock
cultures in 40% glycerol at 80C. G. vaginalis was
grown for 48 h at 37C on horse blood agar plates
and the colonies of bacteria were then scraped from
the agar surface using a spreader and HIB. The cell
suspension was then diluted in HIB and plated onto
horse blood agar plate to get approximately 100
colony forming units (CFUs) per plate. A blank disc
(Oxoid) was placed at the centre of each inoculated
plate and 100 mL of drug standard solution in SVF or
release medium containing MTZ was added to the disc.
The plates were incubated at 37C for 48 h under anaer-
obic conditions and the diameter of the zone of inhib-
ition surrounding the disc was measured. The relative
antibacterial activity of MTZ released from PCL matri-
ces was calculated by comparison with the zone of
inhibition obtained using non-formulated drug solu-
tions of MTZ of the same concentration. SVF and
release media used for incubation of blank PCL matri-
ces were used as controls.
Results and discussion
Morphology of PCL matrices
MTZ-loaded PCL matrices prepared by rapidly cooling
suspensions of drug powder in PCL solution exhibit
flexibility, uniformity of structure and an absence of
large cracks and voids in the sample surface and inter-
ior. SEM examination of drug-free PCL matrices
revealed a nodular type of morphology and irregular
shaped pores with dimensions of 2–4 mm (Figure 1a).
The surface of MTZ-loaded matrices exhibited a flat
texture (Figure 1b), probably, resulting from contact
of the matrix with the mould wall. Fine fissures were
observed in certain areas along with evidence of trape-
zoidal-shaped drug crystals 1–2 mm in size. The internal
structure of MTZ-loaded PCL matrices exhibited a
woven, lamellar type of morphology (Figure 1c) and
the characteristic microporous morphology of the
Figure 1. Morphology of drug-free and 5.4% metronidazole (MTZ)-loaded PCL matrices. (a) Interior of drug-free PCL matrix,
(b) surface of MTZ-loaded PCL matrix, (c) interior of MTZ-loaded PCL matrix and (d) interior of MTZ-loaded PCL matrix showing
presence of drug crystals (arrowed). PCL: polycaprolactone.
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PCL phase consisting of 2–5 mm pores. Lozenge-shaped
or trapezoidal drug crystals are visible at higher mag-
nification (Figure 1d, arrowed).
MTZ loading of PCL matrices
The actual loading of MTZ in PCL matrices and
the corresponding theoretical loading are presented
in Table 1. Actual drug loading tended to
increase towards the base of the moulding, indicating
sedimentation of larger drug particles before crystallisa-
tion and hardening of the PCL phase occurred dur-
ing cooling to 80C. The variation of drug
loading throughout samples was typically confined
to 1–2% but a larger spread in actual drug loading
(6–10%) was observed for PCL matrices prepared
using 15% w/v PCL solution.
Average MTZ loadings of 2.0%, 5.4%, 8.1% and
10.6% w/w were measured in PCL matrices corres-
ponding to theoretical loadings of 5%, 10%, 15%
and 20% w/w, resulting in fairly low incorporation effi-
ciencies of 40–54% (Table 1). These findings may be
explained by the relative solubility of MTZ in the solv-
ents used for matrix production. The solubility of MTZ
in methanol, acetone and ethanol is 32.2, 20.7 and
5.0mg/mL,24 respectively. The solubility of MTZ in
the ethanol phase used to extract acetone from the har-
dened PCL matrices results in partition of MTZ and
elution from the matrix. Despite loss of drug from the
matrix, the solvent extraction stage is essential to avoid
shrinkage of the PCL matrix following crystallisation
and drying which can result in cracking of the material.
Wang et al. found that the use of ethanol instead of
methanol for acetone extraction resulted in an increase
in catalase loading of PCL matrices22 due to the lower
solubility of the enzyme in ethanol. Ethanol was also
used instead of methanol in the present study to exploit
the lower solubility of MTZ in ethanol and thus reduces
drug loss.
Thermal analysis of matrices
DSC analysis revealed more than doubling of the crys-
talline content of PCL matrices from around 33% to
76% with increasing MTZ loading of the material from
0 to 8.1% w/w (Table 2). Previous studies by Chang
et al. revealed crystallinity levels of 50–75% for drug-
free PCL matrices and both increases and decreases in
PCL crystallinity depending on the type of drug mol-
ecule incorporated in the matrix.21 Progesterone inclu-
sion (10%) resulted in a major reduction of crystallinity
of around 12% from 66% to 54%,21 whereas gentami-
cin sulphate particulates increased the crystallinity of
PCL matrices by 4–8%. Progesterone particulates
were considered to inhibit PCL crystal nucleation and
growth, while gentamicin sulphate particles acted as
nucleating agents to enhance PCL crystallisation. The
significant increase in crystallinity of the PCL phase
with MTZ loading measured in the present study indi-
cates the strong effect of the dispersed drug particles on
nucleation and crystal growth of PCL. Detailed inves-
tigations of the influence of processing conditions on
drug particle crystallinity, to control drug dissolution
behaviour and bioavailability, for example, have been
reported extensively in the scientific literature.25,26
However, we have found no reports, apart from our
previous studies which document the effect of drug
presence on the crystallinity of excipients used in the
formulation of drug delivery devices. The particles of
MTZ appear to promote heterogeneous or epitaxial
crystallisation of PCL, which is known to be influenced
by similarities in the crystal lattice of the substrate and
crystallising polymer and also by the surface topog-
raphy of the substrate (defects, steps and terraces).27
The lower crystallinity of the drug-free PCL phase in
the present study compared with samples produced by
Chang et al. reflects rapid cooling of the PCL solution
compared with the room temperature, precipitation
technique employed by Chang et al.21 Rapid cooling
Table 2. Thermal analysis of metronidazole-loaded PCL
matrices.
Theoretical
drug
loading
(% w/w)
Actual
drug
loading
(% w/w) % Crystallinity
Glass
transition
temperature
(Tg) (
C)
0 0 33.4 2.3 60.1 0.6
5 2.9 42.4 1.9 58.1 0.4
10 5.4 56.1 2.2 56.5 0.4
15 8.1 74.8 1.6 55.6 0.5
20 10.6 75.6 1.2 54.5 0.6
PCL: poly (e-caprolactone).
Table 1. Loading and incorporation efficiency of metronidazole
in PCL matrices prepared using the rapid cooling technique.
Theoretical drug
loading (% w/w)
Actual
loading
(% w/w)
Incorporation
efficiency (%)
5 2.0 0.5 40.0 6.6
10 5.4 0.8 54.0 8.3
15 8.1 1.3 54.0 8.8
20 10.6 0.7 53.0 3.4
PCL: poly (e-caprolactone).
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restricts polymer chain mobility and crystal growth.
The glass transition temperature indicates the reversible
change in the amorphous regions of a polymer from a
hard and relatively brittle condition to a viscous or
rubbery state. The increase in Tg found with increasing
MTZ loading (Table 2) indicates an interference or
restriction of PCL chain mobility due to the presence
of the dispersed drug particles in the matrix.
Hardness testing of PCL matrices
The hardness values determined by texture analysis for
MTZ-loaded PCL matrices are shown in Table 3.
Matrices containing low drug loadings (2.0% w/w)
exhibited similar hardness to unloaded samples.
However, the matrix hardness decreased significantly
by a factor of almost 2.5 when the drug loading was
increased to 5.4%. The highest loaded samples (10.6%)
exhibited a further decrease in hardness to around
900mN/mm2 indicating that excessive drug loading
causes deterioration and weakening of the matrix struc-
ture, probably by micro-cracking effects which are also
influential in relation to drug release behaviour.28 The
hardness of the pEVA IVR was found to be 9280mN/
mm2 which is almost 2.5 times more than the 2%MTZ-
loaded PCL samples. Thus microporous PCL IVRs
potentially offer scope for improving user comfort com-
pared with conventional materials. The work of inden-
tation (determined by measurement of the area under
the force/displacement curve) essentially reveals a
major (65%) deterioration in material toughness com-
pared with drug-free matrices at relatively low levels of
drug incorporation around 5% w/w. This factor
requires careful consideration when optimising the
properties of IVR devices, based on MTZ-loaded
PCL matrices since adequate mechanical properties
are required to withstand the flexural loads experienced
during insertion and during device residence in
the vagina and thus ensure successful clinical
performance.
In vitro release of MTZ from PCL matrices
Drug release from PCL matrices featuring dispersed
drug particles is governed by a number of factors
including drug loading, uptake of release medium and
drug solubility in the fluid phase, matrix porosity and
the rate of drug diffusion in fluid-filled pores of the
material. Since PCL exhibits a bioresorption time in
excess of two years, the detailed pore structure (pore
size, connectivity and tortuosity) exerts a major influ-
ence on drug transport from the matrix. The release
profiles of MTZ from PCL matrices in SVF at 37C
are presented in Figure 2.
Following a large burst release phase in day 1, grad-
ual drug release occurs over the following 12 days
giving rise to an almost linear profile. The magnitude
of the burst release phase increases with drug loading of
the matrix from around 35% for 2.0% loaded matrices
to almost 60% for the most highly loaded PCL matrix
(10.6%). This behaviour suggests the presence of large
amounts of drug particles at or close to the matrix sur-
face and is supported by the SEM observations
described above (Figure 1b). In the case of low drug
loadings, gradual release of MTZ is expected to occur
predominantly through interconnected pores and chan-
nels inherent in the microporous PCL matrix since the
separation of drug particles will not favour formation
of interconnected macropores by dissolution of con-
tacting drug particles. Increasing numbers of intercon-
nected macropores, fissures and channels are expected
in the highly loaded systems, due to contact of drug
particles and micro-cracking effects,28 which facilitate
entry of release medium and enhance drug dissolution
and extraction. Around 80% of the drug load is
released from all samples by day 12 demonstrating in
general high pore interconnectivity and thus delivery
Figure 2. Cumulative (%) release of MTZ from PCL matrices in
SVF at 37C. MTZ: metronidazole; PCL: polycaprolactone; SVF:
simulated vaginal fluid.
Table 3. Hardness testing of PCL matrices.
Drug loading
(% w/w)
Hardness
(mN/mm2)
Work
done (mJ)
0 3986 210 14.3 2.0
2.0 3841 190 13.2 1.5
5.4 1522 75 5.0 0.7
8.1 1268 62 4.6 1.1
10.6 888 32 2.9 0.9
PCL: poly (e-caprolactone).
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efficiency. The amount of drug released daily from the
PCL matrices is presented in Figure 3. A minimum
release amount of 51 mg of MTZ per day was measured
at day 10.
Analysis of drug distribution using Raman
spectroscopy
The Raman spectra of PCL show a characteristic peak
in the region of 3000 cm1 due to C–H stretching; small
peaks at around 1800–1700 cm1 are assigned to C¼O
stretching, while the peak at 1500 cm1 is attributed to
dCH2 and that at 1200–1280 cm
1 is due to CH2.
29
The spectra of PCL matrices revealed an absence of
those molecules characteristic of the solvents used
(acetone, ethanol) in matrix preparation.
Raman peaks for MTZ at 1500–1650 cm1 are due
to C¼N stretching. In-plane and out-of-plane deform-
ation vibrations are normally observed as sharp but
weak to medium intensity bands in the region 1300–
750 cm1. Small peaks around 800 cm1 are due to
NO2 group scissoring, wagging, rocking and twisting.
30
The Raman spectra presented in Figure 4 were gen-
erated at radial positions starting from the centre of a
5.4% MTZ-loaded PCL matrix disk and moving
toward the edge. The distinct peaks in the region of
3000 and 1000–1500 cm1 are due to the presence of
the polymer and drug, respectively. The traces clearly
indicate the change in peak intensity corresponding to
differences in drug concentration at different positions
within the sample, which reflects the dispersion of drug
powder within the PCL matrix. The high
intensity Raman spectra obtained at points along the
sample edge for the 5.4% MTZ-loaded PCL matrix
(Figure 5) confirm that high concentrations of drug
are present at the matrix surface. These findings sup-
port the SEM images of drug crystals located at the
sample surface and explain the high burst release
behaviour of MTZ at day 1 of release testing (Figure 2).
Antibacterial testing
G. vaginalis is an anaerobic, b-haemolytic, oxidase-
negative, catalase-negative, gram variable bacterium,
which is detected in all women diagnosed with BV
and plays an important role in its pathogenesis.5
2100
2000
1900
1800
1700
1600
1500
1400
1300
1200
1100
1000
900
800
700
600
500
400
300
200
100
Transverse section of  PCL matrix
R
am
an
 in
te
ns
ity
50010001500200025003000
Raman shift (cm-1)
Figure 4. Raman spectra obtained at different radial positions in a transverse section of 5.4% MTZ-loaded PCL matrix. MTZ:
metronidazole; PCL: polycaprolactone.
Figure 3. Amount of metronidazole (MTZ) release (mg) from
PCL matrices in SVF at 37C. PCL: polycaprolactone; SV: simu-
lated vaginal fluid.
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The antibacterial activity of non-formulated MTZ and
drug released from PCL matrices into SVF against G.
vaginalis was investigated using a disc diffusion assay
to determine the effect of matrix formulation and
matrix residence time in SVF on drug activity and
to assess any implications for in vivo performance
and dosing regimens A zone of inhibition increasing
from 7 to 20mm diameter was observed for control
drug solutions in SVF with increasing concentration
from 25 to 125 mg/mL (Figure 6). No zone of inhib-
ition was observed in the case of control samples com-
prising SVF alone or release media obtained from
drug-free PCL matrices.
Release media of days 2, 4, 6, 8 and 10 have been
selected for the comparison with the standard drug. A
linear relationship was observed between MTZ concen-
tration and the diameter of the zone of inhibition, with
a high correlation coefficient (R2¼ 0.962). The relative
antibacterial activity (%) of MTZ released from 5.4%
drug-loaded PCL matrices into SVF was obtained by
comparing the diameter of the zone of inhibition
obtained for standard MTZ solution and MTZ-con-
taining release media at equivalent drug concentrations.
A high relative antibacterial activity (88–97%) was
exhibited by released drug over a 10-day release
period (Figure 7). The relatively small decrease in
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Figure 5. Raman spectra obtained at different edge points in a transverse section of 5.4% MTZ-loaded PCL matrix. MTZ: metro-
nidazole; PCL: polycaprolactone.
Figure 6. Relationship between concentration of MTZ and
diameter of zone of inhibition against G. vaginalis. MTZ: metro-
nidazole; G. vaginalis: Gardnerella vaginalis.
Figure 7. Relative activity (%) of MTZ released from 5.4% drug-
loaded PCL matrices in SVF at 37C over 10 days. MTZ:
metronidazole; PCL: polycaprolactone; SVF: simulated
vaginal fluid.
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antibacterial activity over the course of the study may
be due to prolonged exposure of the drug within the
PCL matrix to elevated temperature (37C) and the
fairly complex biochemical environment presented by
the SVF.
Based on the minimum daily amount of MTZ
released from PCL matrices (51 mg released into
10mL SVF at day 10 from a 5.4% drug-loaded
matrix) the predicted concentrations of drug which
would be released from an intra-vaginal ring (produced
from a PCL matrix) into vaginal fluid are above the
minimum inhibitory concentration (MIC) against G.
vaginalis (2–12.8mg/mL).31 This assessment is based
on the linear length of an intra-vaginal ring of
150mm (outer diameter 58mm, inner diameter
38mm) and weight (1.5 g) being approximately 3.5
times that of the studied matrices (45mm, 0.4 g). The
minimum release amount of 5.1 mg/mL/day corres-
ponds to a drug release rate from a PCL IVR of
around 18 mg/mL/day. It is further assumed that the
in vitro release rate from PCL matrices is similar to
the in vivo release rate from a PCL vaginal ring and a
maximum vaginal fluid turnover rate of 8mL/day
applies. These estimates do not take into account the
complex variations in vaginal fluid volume and bio-
chemical composition over time, or the possibility of
systemic uptake of drug.
Conclusion
The basic modelling approach applied predicts that
PCL matrices incorporating MTZ are potentially cap-
able of eradicating in vivo one of the principal micro-
organisms implicated in the pathogenesis of BV. IVRs
produced from microporous PCL matrices would offer
advantages over MTZ vaginal gels in terms of reduced
frequency of application and oral dosage forms in
terms of avoidance of side effects and as a result war-
rants further investigation.
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